Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

9.3%

7 terminated/withdrawn out of 75 trials

Success Rate

90.4%

+3.9% vs industry average

Late-Stage Pipeline

16%

12 trials in Phase 3/4

Results Transparency

39%

26 of 66 completed trials have results

Key Signals

1 recruiting26 with results7 terminated

Enrollment Performance

Analytics

Phase 1

40(54.1%)

Phase 2

22(29.7%)

Phase 3

9(12.2%)

Phase 4

3(4.1%)

74Total

Phase 1(40)

Phase 2(22)

Phase 3(9)

Phase 4(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (75)

Showing 20 of 75 trials

NCT05696717Phase 3Active Not Recruiting

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

Role: lead

NCT07133880Phase 4Recruiting

Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators

Role: collaborator

NCT04315558Phase 2Completed

Revefenacin in Acute Respiratory Insufficiency in COPD

Role: collaborator

NCT00391820Phase 2Completed

Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)

Role: collaborator

NCT01467726Phase 1Completed

Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects

Role: collaborator

NCT05165485Phase 4Completed

Phase 4 COPD and Suboptimal Inspiratory Flow Rate

Role: lead

NCT03635112Phase 2Terminated

Efficacy and Safety of TD-1473 in Crohn's Disease

Role: lead

NCT03829657Phase 3Terminated

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Role: lead

NCT04095793Phase 3Terminated

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Role: lead

NCT03758443Phase 2Terminated

Efficacy & Safety of TD-1473 in Ulcerative Colitis

Role: lead

NCT03920254Phase 2Terminated

TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study

Role: lead

NCT02705755Phase 2Completed

TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)

Role: lead

NCT03750552Phase 3Completed

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Role: lead

NCT01458340Phase 2Completed

A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Role: lead

NCT04150341Phase 2Completed

Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response

Role: lead

NCT04402866Phase 2Completed

TD-0903 for ALI Associated With COVID-19

Role: lead

NCT01693692Phase 2Completed

Phase 2 Study of TD-9855 to Treat Fibromyalgia

Role: lead

NCT03573817Phase 3Completed

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

Role: collaborator

NCT03095456Phase 3Completed

Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD

Role: collaborator

NCT02040792Phase 2Completed

A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

Role: collaborator